{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-23-000007","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.394187+00:00","generated_at":"2026-06-18T07:17:55.402312+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pliant reports Q4 2022 net loss $35.1M; positive bexotegrast data, $287.5M raise extends runway to H2 2026","bullets":["Bexotegrast 320 mg in IPF Phase 2a showed statistically significant FVC increases at 12 weeks; no drug-related severe AEs.","Closed $287.5M equity offering in Jan 2023; net proceeds $269.9M, extending cash runway into second half of 2026.","Q4 2022 net loss $35.1M ($24.5M prior year); R&D expenses $25.1M, G&A $14.3M.","24-week INTEGRIS-IPF 320 mg data expected Q2 2023; Phase 2b IPF trial initiation mid-2023.","EMA granted Orphan Drug designation for bexotegrast in IPF; Novartis terminated PLN-1474 deal and returned rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-23-000007","json":"https://secwatch.observer/filing/0001746473-23-000007.json","markdown":"https://secwatch.observer/filing/0001746473-23-000007.md","text":"https://secwatch.observer/filing/0001746473-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/0001746473-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/plrx-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:17:55.402312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4583a9d8bf2e732ce29beb9d4c170ef9af5c176","claim":"PLIANT THERAPEUTICS, INC. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"On March 9, 2023, Pliant Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/0001746473-23-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}